Evolution of multidrug resistance in Plasmodium falciparum: A longitudinal study of genetic resistance markers in the Greater Mekong subregion

Imwong, M; Suwannasin, K; Srisutham, S; Vongpromek, R; Promnarate, C; Saejeng, A; Phyo, AP; Proux, S; Pongvongsa, T; Chea, N; Miotto, O; Tripura, R; Nguyen Hoang, C; Dysoley, L; Ho Dang Trung, N; Peto, TJ; Callery, JJ; van der Pluijm, RW; Amaratunga, C; Mukaka, M; von Seidlein, L; Mayxay, M; Thuy-Nhien, NT; Newton, PN; Day, NPJ; Ashley, EA; Nosten, FH; Smithuis, FM; Dhorda, M; White, NJ; Dondorp, AM

Journal article

Evolution of multidrug resistance in Plasmodium falciparum: A longitudinal study of genetic resistance markers in the Greater Mekong subregion

Abstract:: Increasing resistance in Plasmodium falciparum to artemisinins and their artemisinin combination therapy (ACT) partner drugs jeopardizes effective antimalarial treatment. Resistance is worst in the Greater Mekong subregion. Monitoring genetic markers of resistance can help to guide antimalarial therapy. Markers of resistance to artemisinins (PfKelch mutations), mefloquine (amplification of P. falciparum multidrug resistance-1 [PfMDR1]), and piperaquine (PfPlasmepsin2/3 amplification and specific P. falciparum chloroquine resistance transporter [PfCRT] mutations) were assessed in 6,722 P. falciparum samples from Vietnam, Lao People’s Democratic Republic (PDR), Cambodia, Thailand, and Myanmar between 2007 and 2019. Against a high background prevalence of PfKelch mutations, PfMDR1 and PfPlasmepsin2/3 amplification closely followed regional drug pressures over time. PfPlasmepsin2/3 amplification preceded piperaquine resistance-associated PfCRT mutations in Cambodia and reached a peak prevalence of 23/28 (82%) in 2015. This declined to 57/156 (38%) after first-line treatment was changed from dihydroartemisinin-piperaquine to artesunate-mefloquine (ASMQ) between 2014 and 2017. The frequency of PfMDR1 amplification increased from 0/293 (0%) between 2012 and 2017 to 12/156 (8%) in 2019. Amplification of PfMDR1 and PfPlasmepsin2/3 in the same parasites was extremely rare (4/6,722 [0.06%]) and was dispersed over time. The mechanisms conferring mefloquine and piperaquine resistance may be counterbalancing. This supports the development of ASMQ plus piperaquine as a triple artemisinin combination therapy.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Imwong, M., Suwannasin, K., Srisutham, S., Vongpromek, R., Promnarate, C., Saejeng, A., Phyo, A. P., Proux, S., Pongvongsa, T., Chea, N., Miotto, O., Tripura, R., Nguyen Hoang, C., Dysoley, L., Ho Dang Trung, N., Peto, T. J., Callery, J. J., van der Pluijm, R. W., Amaratunga, C., … Dondorp, A. M. (2021). Evolution of multidrug resistance in Plasmodium falciparum: A longitudinal study of genetic resistance markers in the Greater Mekong subregion. Antimicrobial Agents and Chemotherapy, 65(12).

MLA Style

Imwong, M, et al. “Evolution of Multidrug Resistance in Plasmodium Falciparum: A Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion.” Antimicrobial Agents and Chemotherapy, vol. 65, no. 12, 2021.

Chicago Style

Imwong, M, K Suwannasin, S Srisutham, et al. 2021. “Evolution of Multidrug Resistance in Plasmodium Falciparum: A Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion.” Antimicrobial Agents and Chemotherapy 65 (12).
Print